Today's Date: June 9, 2023
Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023   •   Providing LGBTQI+ people with a safe home in Canada   •   Saudi Arabia: Modern means of transportation for easier Hajj   •   IgGenix Demonstrates Potential for an IgG4 Monoclonal Antibody-based Approach to Treating Peanut Allergy   •   CGTN: China stresses green development, ethnic unity in modernization drive   •   Sophisticated Utility Vehicle: all-new 2024 Lexus GX Redefines SUV   •   ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at   •   TIO EQUITY ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages Tingo Group, Inc. Investors with Losses in Excess of $100K to Secur   •   Hengtong Optic-Electric Releases 2022 ESG Report at the PT Expo   •   SoftwareReviews Reveals the Top ESG Software Solutions That Enable Organizations to Build a Culture of Purpose and Sustainabilit   •   USCIB Releases Pride Month Statement, Supporting Equality and Inclusion   •   Children's Miracle Network Hospitals® Celebrates 40th Anniversary with Celebrity Friends and Supporters   •   Perfuze Announces Appointment of New Chair of the Board   •   Ventas Realty, Limited Partnership Announces Upsize and Pricing of $750 Million of Exchangeable Senior Notes   •   Stallergenes Greer Showcases Clinical Relevance and Persisting Benefits of Its Allergen Immunotherapy Treatments at 2023 EAACI C   •   BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congres   •   A New Era of Three-Row Luxury: The First-Ever Lexus TX   •   Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presen   •   Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematol   •   Fairmont Mayakoba to host exclusive 2023 pride celebration
Bookmark and Share

BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases

OTTAWA, Ontario , March 22 /Businesswire/ - BIOTECanada welcomes the government’s dedicated investment of $1.5 B over 3 years to advance effective access to medicines, improve evidence and decisions for the care of patients with rare diseases. The integrated approach, bringing federal, provincial and territorial governments together with national clinical practice expertise networks including clinicians, researchers and industry will be key to creating a national access program to address the long-standing gap in care for patients with rare diseases.

“Canada is home to dozens of small companies from university beginnings and global companies bringing solutions to meet the needs of these highly complex illnesses impacting thousands of Canadian patients and their families. Today’s announcement is an important initial step which sends a strong message to investors and researchers of Canada’s commitment to addressing the need of patients globally. The industry welcomes the opportunity to work with the government to support evidence-based decision making, including data collection, patient registries, gaining evidence and increasing regulatory capacity. Together, successfully building Canada’s capacity in these areas will support the delivery of ground-breaking medicines for Canadians,” commented Andrew Casey President and CEO BIOTECanada.

Canada has been lacking a cohesive strategy to address the needs of rare disease patients for decades. Most other developed nations have had systems of care in place serving the needs of patients, improving clinical research and regulatory capacity while working collaboratively with industry. With the federal commitment outlined today by federal Minister of Health Duclos, Canada is positioned to ensure rare disease patients benefit from the expanding research and development underway here in Canada and globally.

“BIOTECanada’s network of member companies are some of the many companies globally developing breakthrough medicines and therapies to address the unique medical needs associated with rare disorders. Importantly, many global pharma companies are investing in and/or partnering with Canadian companies to advance innovative biotech solutions emerging from Canadian universities and research labs. Remarkable new technologies and therapies are on the horizon, including some being developed by Canadian biotech companies. In this context, the industry looks forward to working with federal and provincial governments on the implementation of this strategy and the corresponding regulatory mechanisms to facilitate greater access for patients,” offered Casey.

STORY TAGS: North America, Canada, Research, Public Policy/Government, Healthcare Reform, Biotechnology, Other Health, Health, State/Local, Pharmaceutical, Science, Ontario,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News